Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Owais Malick

Advanced Heart Failure and Transplant Cardiology Downers Grove, IL Medical Doctor

NPI 1326337130 CMS profile 1279558

3825 Highland Ave, Downers Grove, IL 60515

Open in the dashboard

General payments

$77,777

194 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Owais Malick of Downers Grove, IL is reported in the CMS Open Payments database as having received $77,777 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,836 49
2024 General $27,794 41
2023 General $23,486 56
2022 General $8,575 27
2021 General $588 9
2020 General $192 5
2019 General $305 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Owais Malick
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Owais Malick were reported at $16,836. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Owais Malick Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $305 $863 $224–$4,562 $163
2020 $192 $452 $122–$3,992 $114
2021 $588 $550 $159–$3,571 $132
2022 $8,575 $729 $221–$4,357 $149
2023 $23,486 $1,002 $309–$5,827 $160
2024 $27,794 $931 $273–$5,204 $164
2025 $16,836 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Actelion Pharmaceuticals US, Inc. $63,748 81 payments
  2. Pfizer Inc. $7,467 9 payments
  3. Abiomed $2,565 10 payments
  4. Abbott Laboratories $2,396 68 payments
  5. CVRx, Inc. $307 3 payments
  6. Ancora Heart, Inc. $299 2 payments
  7. United Therapeutics Corporation $205 2 payments
  8. Novo Nordisk Inc $175 3 payments
  9. Edwards Lifesciences Corporation $152 1 payment
  10. Cardiva Medical, Inc. $96 1 payment
  11. Other $367 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $61,430 30 payments
  2. Food and Beverage $6,878 144 payments
  3. Travel and Lodging $6,445 19 payments
  4. Consulting Fee $3,024 1 payment
Products named General payments · program years 2019–2025
  1. UPTRAVI $63,315 79 payments
  2. OPSUMIT $59,799 60 payments
  3. VYNDAQEL $7,467 9 payments
  4. Impella $2,432 9 payments
  5. CARDIOMEMS Heart failure $978 40 payments
  6. CARDIOMEMS Structural Heart $973 18 payments
  7. Barostim Neo System $307 3 payments
  8. AccuCinch $299 2 payments
  9. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $155 2 payments
  10. PASCAL $152 1 payment
  11. Other $1,235 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

3,526

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$4,220,527

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

39.5%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 71 $1,772,103
Opsumit Macitentan Brand 42 $531,629
Entresto Sacubitril/Valsartan Brand 415 $516,407
Jardiance Empagliflozin Brand 402 $399,891
Tyvaso Dpi Treprostinil Brand 13 $298,531
Adempas Riociguat Brand 11 $156,514
Eliquis Apixaban Brand 120 $140,097
Farxiga Dapagliflozin Propanediol Brand 146 $138,938
Camzyos Mavacamten Brand 12 $105,239
Xarelto Rivaroxaban Brand 54 $64,322

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$154,811

Of which drugs: $1,341

Medicare patients

860

Average age 78

Services billed

2,239

440 women, 420 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 68%
Ischemic heart disease 63%
Chronic kidney disease 56%
Arthritis 56%
Atrial fibrillation 52%
Diabetes 43%
COPD 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, perflutren lipid microspheres, per ml Q9957 Office 21 44 $1,341

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $10,967
$10,967 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $10,901
$10,901 42 —
VYNDAQEL
  • PFIZER INC. $5,524
$5,524 — —
Wegovy
  • Novo Nordisk Inc $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record